DF/HCC Program Affiliation

Kidney Cancer
Prostate Cancer

Research Abstract

TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells.

Publications

• Li W, Zhang X, Olumi AF.MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L).Cancer Res 2007 Mar 1;67(5):2247-55.
  17332355
• San Francisco IF, Regan MM, Dewolf WC, Olumi AF.Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.J Urol 2006 Apr;175(4):1341-5; discussion 1345-6.
  16515994
• Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.Cancer Res 200
  15466204
• San Francisco IF, DeWolf WC, Peehl DM, Olumi AF.Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.Int J Cancer 2004 Nov 1;112(2):213-8.
  15352032
• Olumi AF.A critical analysis of the use of p53 as a marker for management of bladder cancer.Urol Clin North Am 2000 Feb;27(1):75-82, ix.
  10696247
• Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR.Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.Cancer Res 1999 Oct 1;59(19):5002-11.
  10519415